Compare DoorDash Inc (DASH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Zoetis Inc — how do they compare? DoorDash Inc trades at $195.93 (market cap $83.07B), while Zoetis Inc trades at $73.96 (market cap $30.20B). The key difference: DoorDash Inc is far larger — about 2.8× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Zoetis Inc for 70 Days on average.
| DASH | ZTS | |
|---|---|---|
Market Cap | $83.07B | $30.20B |
Volume | 3,242,567 | 6,175,327 |
Sector | Media | Health |
52-Week High | $275.44 | $147.53 |
52-Week Low | $146.60 | $69.09 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $81.03B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $13.72 billion in 2025, and achieved profitability with a net income margin of 6.81%. Recent developments include the launch of AI-powered text ordering and drone delivery expansion, signaling innovation in its core delivery business.
The outlook is positive with a consensus price target of $255.80, though high valuation multiples and mixed quarterly earnings misses pose risks. Investor sentiment is bolstered by analyst optimism, but regulatory scrutiny and competitive pressures remain key concerns for sustained growth.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
